SMPD2: Potential Drug Target for Neurodegenerative Diseases (G6610)

Target Name: SMPD2

NCBI ID: G6610

SMPD2

SMPD2: Potential Drug Target for Neurodegenerative Diseases

SMPD2 (Small molecule potentiator of NSMASE1), a protein encoded in the gene NSMASE1, has been identified as a potential drug target or biomarker in the field of neurodegenerative diseases.NSMASE1 is a enzyme involved in the production of neurotransmitters, such as dopamine, in the brain. The dysfunction of this enzyme has been implicated in the development and progression of various neurodegenerative diseases, including Parkinson's disease, Alzheimer's disease, and Huntington's disease.

SMPD2 has been shown to play a crucial role in the regulation of NSMASE1 activity. It is a protein that can enhance the activity of NSMASE1, leading to an increase in the production of neurotransmitters. This increase in neurotransmitters can have a beneficial effect on the brain, but if it occurs at an inappropriate level or if it is not properly regulated, it can lead to the development of neurodegenerative diseases.

SMPD2 has also been shown to interact with other proteins involved in neurodegenerative diseases. For example, it has been shown to interact with the protein brain-derived neurotrophic factor (BDNF), which is a protein involved in the treatment of neurodegenerative diseases. The interaction between SMPD2 and BDNF has been shown to play a role in the development of neurodegenerative diseases.

SMPD2 has also been shown to be involved in the regulation of neurotransmitter synthesis. It is a protein that can bind to the neurotransmitter receptors, such as dopamine and serotonin, and enhance their activity. This increase in neurotransmitter activity can have a beneficial effect on the brain, but if it occurs at an inappropriate level or if it is not properly regulated, it can lead to the development of neurodegenerative diseases.

SMPD2 has also been shown to be involved in the regulation of gene expression. It is a protein that can bind to the DNA and enhance the activity of the RNA polymerase, leading to an increase in the production of a protein called doublecortin (DcN). Doublecortin is a protein that is involved in the regulation of neurotransmitter synthesis and has been shown to play a role in the development and progression of neurodegenerative diseases.

SMPD2 has also been shown to be involved in the regulation of cellular signaling pathways. It is a protein that can bind to the protein p75, which is involved in the regulation of neurotransmitter release. The interaction between SMPD2 and p75 has been shown to play a role in the regulation of neurotransmitter release and has implications for the development and progression of neurodegenerative diseases.

SMPD2 has also been shown to be involved in the regulation of inflammation. It is a protein that can bind to the protein nuclear factor kappa B (NFKB), which is involved in the regulation of inflammation. The interaction between SMPD2 and NFKB has been shown to play a role in the regulation of inflammation and has implications for the development and progression of neurodegenerative diseases.

SMPD2 has also been shown to be involved in the regulation of cellular stress response. It is a protein that can bind to the protein heat shock protein (HSP70), which is involved in the regulation of cellular stress response. The interaction between SMPD2 and HSP70 has been shown to play a role in the regulation of cellular stress response and has implications for the development and progression of neurodegenerative diseases.

SMPD2 has also been shown to be involved in the regulation of neurotrophic factor (NTF) signaling pathways. It is a protein that can bind to the protein NTF, which is involved in the regulation of neurotransmitter release.

Protein Name: Sphingomyelin Phosphodiesterase 2

Functions: Catalyzes, at least in vitro, the hydrolysis of sphingomyelin to form ceramide and phosphocholine (PubMed:10608884). Also hydrolyzes 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine (lyso-platelet-activating factor) in vivo (PubMed:10608884). Also acts on 1-acyl-2-lyso-sn-glycero-3-phosphocholine (lyso-PC) and sphingosylphosphocholine (PubMed:10608884, PubMed:14741383)

The "SMPD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMPD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets